Literature DB >> 8757875

Characterization of the murine antibody response to peptides representing the variable domains of the major outer membrane protein of Chlamydia pneumoniae.

E M Peterson1, X Cheng, Z Qu, L M de La Maza.   

Abstract

In an attempt to gain more knowledge about the immunogenicity of the variable domains (VDs) of the major outer membrane protein (MOMP) of Chlamydia pneumoniae, peptides representing these areas were used to immunize BALB/c and C57BL/6 mice. Antisera to the peptides and to peptides conjugated to keyhole limpet hemocyanin (KLH) were characterized by their ability to recognize the immunizing peptide and elementary bodies (EBs) of C. pneumoniae by enzyme-linked immunosorbent assay (ELISA) and Western blot (immunoblot). In addition, antiserum was analyzed for its molecular specificity by a pepscan as well as its in vitro neutralizing ability. In general, results obtained with antisera to the peptides paralleled the results obtained with the antisera to the KLH-conjugated peptides except that the titers or strength of reaction in the assays was less. Antisera to the VDs in both strains of mice gave ELISA titers to the homologous VD peptide ranging from 1,000 to >64,000. The strength of reactivity with the reduced MOMP as judged by Western blot, in most cases, paralleled the ELISA titer to the peptide. However, only antisera raised in both strains of mice to the VD1 and VD4 peptides reacted strongly with the EBs, suggesting surface exposure of these VDs. In addition, antisera to VD3 from C57BL/6 mice gave strong reactivity to EBs. By pepscan analysis antisera from both strains of mice reacted with several VD1 and VD3 octameric peptides, with weaker reactivity being seen with the octameric peptides in the other two VDs. This was in contrast to antisera raised to EBs of C. pneumoniae TW-183, which identified two immunogenic regions, one in VD1 and the other mapped to VD4. While antisera raised to EBs strongly neutralized the infectivity of C. pneumoniae, none of the peptide antisera was able to neutralize. In addition, peptides to the VDs were not able to block the neutralizing ability of the antisera to EBs of C. pneumoniae. Therefore, these results suggest that the VDs of the MOMP of C. pneumoniae are surface exposed but do not elicit neutralizing antibodies when linear peptides representing them are used as the immunogen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757875      PMCID: PMC174229          DOI: 10.1128/iai.64.8.3354-3359.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.

Authors:  H Schägger; G von Jagow
Journal:  Anal Biochem       Date:  1987-11-01       Impact factor: 3.365

2.  Strategies for epitope analysis using peptide synthesis.

Authors:  H M Geysen; S J Rodda; T J Mason; G Tribbick; P G Schoofs
Journal:  J Immunol Methods       Date:  1987-09-24       Impact factor: 2.303

3.  Protective monoclonal antibodies to Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein determinants.

Authors:  Y X Zhang; S J Stewart; H D Caldwell
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

4.  Nucleotide and deduced amino acid sequences for the four variable domains of the major outer membrane proteins of the 15 Chlamydia trachomatis serovars.

Authors:  Y Yuan; Y X Zhang; N G Watkins; H D Caldwell
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

5.  Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity.

Authors:  E M Peterson; G M Zhong; E Carlson; L M de la Maza
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

6.  Serological response to Chlamydia pneumoniae infection.

Authors:  L A Campbell; C C Kuo; S P Wang; J T Grayston
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

Review 7.  Chlamydia pneumoniae (TWAR).

Authors:  C C Kuo; L A Jackson; L A Campbell; J T Grayston
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

8.  Antigenic analysis of the major outer membrane protein of Chlamydia spp.

Authors:  H D Caldwell; J Schachter
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

9.  Comparison of a single-antigen microimmunofluorescence assay and inclusion fluorescent-antibody assay for detecting chlamydial antibodies and correlation of the results with neutralizing ability.

Authors:  E M Peterson; R Oda; P Tse; C Gastaldi; S C Stone; L M de la Maza
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

10.  Cognitive features of continuous antigenic determinants.

Authors:  H M Geysen; T J Mason; S J Rodda
Journal:  J Mol Recognit       Date:  1988-02       Impact factor: 2.137

View more
  13 in total

1.  Genomic approach for analysis of surface proteins in Chlamydia pneumoniae.

Authors:  Silvia Montigiani; Fabiana Falugi; Maria Scarselli; Oretta Finco; Roberto Petracca; Giuliano Galli; Massimo Mariani; Roberto Manetti; Mauro Agnusdei; Roberto Cevenini; Manuela Donati; Renzo Nogarotto; Nathalie Norais; Ignazio Garaguso; Sandra Nuti; Giulietta Saletti; Domenico Rosa; Giulio Ratti; Guido Grandi
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

2.  Inclusion fluorescent-antibody test as a screening assay for detection of antibodies to Chlamydia pneumoniae.

Authors:  Olga Tapia; Anatoly Slepenkin; Evgueni Sevrioukov; Kathi Hamor; Luis M de la Maza; Ellena M Peterson
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

3.  Temporal expression of type III secretion genes of Chlamydia pneumoniae.

Authors:  Anatoly Slepenkin; Vladimir Motin; Luis M de la Maza; Ellena M Peterson
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

4.  The Role of Chlamydia in Upper Respiratory Tract Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.725

5.  Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals.

Authors:  A Schumacher; A B Lerkerød; I Seljeflot; L Sommervoll; I Holme; J E Otterstad; H Arnesen
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

6.  Current knowledge of Chlamydia pneumoniae and atherosclerosis.

Authors:  M R Hammerschlag
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

7.  Analysis of the humoral immune response to Chlamydia pneumoniae by immunoblotting and immunoprecipitation.

Authors:  A Essig; U Simnacher; M Susa; R Marre
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

8.  Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection.

Authors:  A Kutlin; N Tsumura; U Emre; P M Roblin; M R Hammerschlag
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

9.  Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron.

Authors:  Anatoly Slepenkin; Per-Anders Enquist; Ulrik Hägglund; Luis M de la Maza; Mikael Elofsson; Ellena M Peterson
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

10.  Detection of Chlamydia pneumoniae-specific antibodies binding to the VD2 and VD3 regions of the major outer membrane protein.

Authors:  Marcus Klein; Arne Kötz; Katussevani Bernardo; Martin Krönke
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.